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ROBUST CROSS-PLATFORM DISEASE PREDICTION USING GENE 
EXPRESSION MICROARRAYS  
 
Zhibao Mi, PhD 
University of Pittsburgh, 2008
 
Microarray technology has been used to predict patient prognosis and response to treatment, 
which is starting to have an impact on disease intervention and control, and is a significant 
measure for public health. However, the process has been hindered by a lack of adequate clinical 
validation. Since both microarray analyses and clinical trials are time and effort intensive, it is 
crucial to use accumulated inter-study data to validate information from individual studies. For 
over a decade, microarray data have been accumulated from different technologies. However, 
using data from one platform to build a model that robustly predicts the clinical characteristics of 
a new data from another platform remains a challenge. Current cross-platform gene prediction 
methods use only genes common to both training and test datasets. There are two main 
drawbacks to that approach: model reconstruction and loss of information. As a result, the 
prediction accuracy of those methods is unstable.   
In this dissertation, a module-based prediction strategy was developed to overcome the 
aforementioned drawbacks. By the current method, groups of genes sharing similar expression 
patterns rather than individual genes were used as the basic elements of the model predictor. 
Such an approach borrows information from genes’ similarity when genes are absent in test data. 
By overcoming the problems of missing genes and noise across platforms, this method yielded 
robust predictions independent of information from the test data. The performance of this method 
was evaluated using publicly available microarray data. K-means clustering was used to group 
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genes sharing similar expression profiles into gene modules and small modules were merged into 
their nearest neighbors. A univariate or multivariate feature selection procedures was applied and 
a representative gene from each selected module was identified. A prediction model was then 
constructed by the representative genes from selected gene modules. As a result, the prediction 
model is portable to any test study as long as partial genes in each module exist in the test study. 
The newly developed method showed advantages over the traditional methods in terms of 
prediction robustness to gene noise and gene mismatch issues in inter-study prediction.    
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1.0  INTRODUCTION 
1.1 MICROARRAY TECHNOLOGY AND ITS APPLICATION 
Microarray technology is originated from a nucleotide hybridization technique, Southern 
blotting, where fragmented DNA are spotted on a supporting material, usually celluloid 
membrane and then probed with a known DNA fragment to identify unknown genes (Southern 
1975). However, Southern blotting is limited for single or fewer gene processes. Early 
microarrays were spotted multiple cDNAs onto a miniaturized filter paper or glass slide to 
monitor panel of gene expression profile (Kulesh, Clive et al. 1987; Schena, Shalon et al. 1995). 
Now this miniaturized technology has extended to other molecular studies known as ‘omics’, e.g. 
genomics, transcriptomics, and evolved to many platforms using advanced technologies, such as 
Affymetrix GeneChip,  GE (Amersham) Codelink, Illumina BeadChip, and Agilent SurePrint.  
With the advance of genome sequencing, microarray technology has been developed rapidly 
in many aspects: from hundreds of gene probes to tens of thousands of gene probes, from spotted 
cDNA microarrays to photolithography oligonucleotide gene chips, from manual results reading 
system to automated data processing (Schulze and Downward 2001). Although various 
techniques are involved in microarray technology, the principle of microarray experiments is 
simply nucleotide hybridizations on micro-scaffolds. Use of this technology to systemically 
measure gene expression on a global level has evolved from large scale gene mapping and 
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sequencing (Poustka, Pohl et al. 1986; Cantor, Mirzabekov et al. 1992) to transcript level 
analysis and gene signaling pathway identification (Schena, Shalon et al. 1995; Schulze, Nicke et 
al. 2004), and it has even spread to develop gene signatures for disease classification and 
prognosis prediction (Luo, Duggan et al. 2001; Beer, Kardia et al. 2002; van 't Veer, Dai et al. 
2002; Potti, Mukherjee et al. 2006). No other technology has drawn as much dedicated attention 
in the biomedical field, and microarrays led the way from related gene expression level to human 
global activities.  
1.2 CLINICAL RISK PREDICTION USING GENOMIC TECHNOLOGIES 
Microarray technology is becoming a promising methodology for predicting prognosis and 
response to treatment for cancer patients, and an emerging component for individualized 
medicine. Though many gene signatures developed from microarray technology reported have 
prediction values for various cancer patients, so far only few of them are in clinical practices 
(van 't Veer, Dai et al. 2002; Paik, Shak et al. 2004; Ross, Hatzis et al. 2008). The many others 
are suffering from either lack of a standardized molecular class prediction methods or 
independent clinical validations (Pusztai, Mazouni et al. 2006; Ioannidis 2007; Pusztai and 
Leyland-Jones 2008), which severely hinders the utility of individual genomic information. 
Since microarray analyses and clinical trials are expensive as well as time and effort intensive, 
therefore, to validate information and to predict patient outcomes from individual studies, it is 
crucial to utilize accumulated inter-study data. A stable prediction model requires features 
selected from a large training data set (Dobbin and Simon 2005; Dobbin, Zhao et al. 2008). For 
over a decade, microarray data have been accumulated from different array technologies or 
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different versions within technologies performed on similar clinical samples. However, to use a 
data set or integrated data sets from one platform to build a model that robustly and accurately 
predicts clinical characteristics of a new data set or a new sample from another platform remains 
a challenge (Tan, Downey et al. 2003; Park, Cao et al. 2004); however, the public accessible data 
provide an alternative to validate the genomic information when new clinical trials are 
inapproachable.     
1.3 METHODOLOGICAL ISSUES IN INTER-STUDY MICROARRAY ANALYSES 
Even though performing microarray experiment is straightforward with current automated 
microarray assay systems, accurate use of the genomic information from microarray analysis to 
classify patients or to predict patient prognosis is not trivial. An ideal approach to use genomic 
data for prediction includes microarray data pre-processing, gene selection, and model 
construction based on training study, and finally, the constructed model is validated on an 
independent test data. Commonly in literature, prediction models were cross validated only based 
on the same data used for the model construction (Pusztai and Leyland-Jones 2008). Cross 
validated models are usually under represented or over fitted due to a lack of heterogeneity of 
sampling and do not reveal cross platform problems when training data and test data are from 
different microarray platforms and protocols. A common cross platform problem is missing 
genes when genes in prediction model based on training data cannot be matched to test data. 
Traditional prediction methods using microarray data select individual genes as model 
components. This individual gene-based prediction (GBP) approach is sensitive to cross-
platform missing genes.  
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Current cross-platform gene prediction methods use only those genes common to both 
training and test data sets (Shi, Tong et al. 2004; Irizarry, Warren et al. 2005; Shi, Tong et al. 
2005). One drawback of this approach is that the prediction model has to be reconstructed, 
depending on the test data. Thus, the model cannot be created independent of knowledge about 
the test data. The model elements need to be adjusted every time test data is predicted.  
In addition, because many genes in the training set and not in the test set are ignored, important 
information from the training set may be lost. Finally, the prediction accuracy of the GBP 
methods is unstable. In addition to missing genes, another reason for this instability is that these 
methods are sensitive to gene noise. In this study, a module-based prediction (MBP) method is 
developed to overcome these aforementioned drawbacks. In the MBP, groups of genes sharing 
similar expression patterns rather than individual genes are used as model predictors. Such an 
approach borrows information from genes’ similarity when genes are absent in test sets. By 
overcoming gene noise and avoiding the problem of missing genes across platforms, the MBP 
method was hypothesized to yield robust predictions completely independent of information 
from the test data. The mechanism of the GBP versus the MBP is illustrated in Figure 1.1. 
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Figure 1.1 The GBP method versus the MBP method: The GBP method selects individual 
genes from training samples to construct a prediction model and uses the model to predict new 
sample (A); whereas, the MBP method selects groups of genes to form gene modules and uses 
these modules to construct a prediction model (B). 
1.4 RELEVANT APPROACHES 
Recently, there have been methods developed to use gene cluster information instead of 
individual gene information as predictors although they are not designed to solve the problems 
mentioned above. These methods can be summarized as three categories, metagenes, supergenes, 
and gene pathway modules, sharing a nature of using information of gene clusters. The 
metagene, defined as aggregate patterns of gene expression, was originally proposed by a group 
of researchers from Duke University (West, Blanchette et al. 2001; Spang, Zuzan et al. 2002; 
Huang, Cheng et al. 2003; Pittman, Huang et al. 2004; Potti, Mukherjee et al. 2006; West, 
Ginsburg et al. 2006). The metagene approach first dealt with an array dimension reduction 
either using supervised feature selection based on t test or correlation coefficient (Potti, 
Dressman et al. 2006) or unsupervised K-means clustering (Huang, Cheng et al. 2003), then took 
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the linear combination of the group of genes within cluster (metagene) based on the principal 
component of singular value decomposition (SVD) (Huang, Cheng et al. 2003; Potti, Dressman 
et al. 2006; Potti, Mukherjee et al. 2006) as predictors to fit prediction model (Figure 1.2.A). 
Meanwhile, they try to identify the biological pathways of the metagenes (Bild, Potti et al. 2006; 
Bild, Yao et al. 2006; Potti, Dressman et al. 2006). This method was then modified by group of 
researchers from MIT and Harvard University, whose metagene was extracted from a standard 
preprocessed array data applying nonnegative matrix factorization (NMF) to factor the resulting 
expression matrix and yield a metagene model by deriving the Moore-Penrose pseudoinverse 
matrix, and then the model data set was projected into metagene space and refined by trimming 
outliers using support vector machine (SVM) classifier (Figure 1.2.A). The refined model data 
set was then refactored using NMF and a refined projection map was established by 
pseudoinverse matrix used to analyze new test data set(Tamayo, Scanfeld et al. 2007). The goal 
of metagene methods was to obtain more accurate and stable prediction. A group of researchers 
from Stanford University took a slightly different approach from metagene. They focused on 
gene cluster method, named supergene, in one aspect, to control cluster reproducibility that a 
cluster defined in training dataset (model dataset) can be found in the test dataset (Kapp and 
Tibshirani 2007) and further to take average of gene expressions within cluster at each 
hierarchical level to fit a lasso regression model (Figure 1.2B), yielding a more accurate 
prediction results (Park, Hastie et al. 2007). Another approach of using information of group of 
genes for prediction is pathway module prediction, of which genes are grouped according to their  
functional pathways (Segal, Shapira et al. 2003; Segal, Friedman et al. 2004; Segal, Friedman et 
al. 2005; van Vliet, Klijn et al. 2007; Wong, Nuyten et al. 2008). This method tried to make gene 
clusters more enriched with biological meanings (Figure 1.2C). However, unlike the MBP 
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 Duke Approach Harvard, MIT Approach
Select features K-means clustering
SVD
PCA (metagene)
Bayesian models
NMF (Metagene extraction)
MP pseudo inverse (Metagene projection)
Refine model by eliminating outliers
SVM classification
Microarray data
Hierarchical  clustering
Gene Average 
LASSO
Stanford Approach
Delft, NetherlandsMicroarray compendium
Unsupervised module extraction 
Classification models
Expression Correlation 
Convert expression to module activity
GO, MSDB, KEGG  
Module validation
Inspect modules
A.
B.
C.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Approaches related to the MBP: Metagene approaches (A), Suppergene approach 
(B), Model based on biological pathway approach(C) 
 
 
 
method being proposed, none of these methods was targeted to fully utilize gene information of 
training data or to deal with missing genes in the test dataset. A comparison of these methods is 
shown in Table 1.1. Their models still involve all individual genes. Missing one gene in the 
model will invalid the entire prediction.  
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Table 1.1 Comparison of prediction methods using gene cluster information 
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Methods                   Authors              Institution               Data reduction              Feature selection             Model               Missing controlled     Test dependent  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Metagene               Huang et al               Duke               K-means clustering                    SVD             Bayesian decision tree              No                     Yes 
                               Potti   et al                Duke                Pearson correlation                   SVD             Bayesian decision tree              No                      Yes 
                              Tamayo et al       MIT, Harvard                NMF                            pseudoinverse               SVM                               No                     Yes 
Supergene             Park et al                 Stanford           Hierarchical Clustering        average genes             LASSO                             N/A                     N/A 
Pathway Module   van Vliet et al    Delft, Netherland    Pathway Compendia          rank of p-values       Bayes classifier                     No                     N/A 
MBP                      Mi et al                     Pitt                      K-means clustering     representative gene     Multiple classifiers                Yes                      No 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
1.5 THE MBP VERSUS METAGENE APPROACH 
Though both the MBP and metagene approaches use the information from group of genes they 
are different by nature. In metagene approach, a subset of genes is selected by either supervised 
(Potti, Dressman et al. 2006) or unsupervised method (Huang, Cheng et al. 2003), then 
projection method, SVD or NMF is used to identifying linear combinations of the subset of 
genes as metagenes (Potti, Dressman et al. 2006; Tamayo, Scanfeld et al. 2007). In this 
approach, if a gene selected in the subset of genes to form a metagene is missing in a test data the 
prediction would fail. Whereas in the MBP approach, all genes are grouped into K subsets by an 
unsupervised clustering method, then top k subsets of genes are selected by a supervised method, 
moderate t statistics (Tibshirani, Hastie et al. 2002), to form prediction modules. For each 
module, a representative gene of group of genes is selected to build prediction model.  In this 
approach, if a gene selected in the prediction module is missing in a test data, a representative 
gene can be chosen from the remaining of genes in the module and the prediction would not fail.  
Further, for construction of a prediction model, only information from one gene subset is used by 
metagene approach, whereas, the information from multiple subsets is used by the MBP 
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approach. The differences indicate that the MBP is robust to gene missing and noise in inter-
study microarray analyses, while, metagene approach is sensitive to the gene missing and noise.     
1.6 HIGHLIGHT OF THE MBP 
The MBP is developed to gain model robustness by solving gene missing and gene noise 
problems, not designed to increase prediction accuracy. As long as no significant loss of 
predictive power or accuracy, the MBP has its practical advantage of clinical utility over the 
GBP.  The MBP development is motivated by two major issues existing in current GBP inter-
study microarray analyses, i.e. information loss and model reconstruction when only common 
genes of both training and test data sets are used. To avoid the issues the prediction models need 
to be built using all genes in training dataset and are independent of test dataset. The GBP 
models are invalid if there are missing genes in the test data. The MBP can overcome the 
problem by borrowing information from the other genes within the same prediction module. 
Further, the MBP is robust to gene noise by selecting a representative gene from a prediction 
module. The prediction robustness to gene missing and noise is inherited from the MBP design.   
1.7 THE GOALS OF THE PROJECT  
The current study was designed to determine whether the MBP method has the similar predictive 
power as the GBP method both within-study and inter-studies and whether the method gained the 
prediction robustness in terms of gene missing and noise. The overall goal to build the MBP 
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model is to yield robust prediction models by solving gene noise and gene missing problems 
existing in the traditional GBP, and to obtain simple models by using all genes of a dataset to 
build prediction model without knowing information of test datasets. The following three goals 
are to be achieved in the dissertation project. 
1.7.1 MBP algorithm development 
Microarray data are preprocessed and standardized. The genes in the standardized array data are 
clustered by K-means and PW-K-means approaches. For those cluster size smaller than a 
threshold δ are merged into their nearest neighbors. The clusters are selected based on the 
moderated t statistics and the representative gene for each selected cluster was determined by 
minimum sum distance among the genes within the cluster. The final prediction model is 
constructed based on the selected representative genes. 
1.7.2 Prediction failure control 
An intrinsic disadvantage of using the GBP to build cross-platform prediction model is that gene 
missing problem can not be solved. The key of solving this problem using the MBP is that when 
a gene or multiple genes are missing in a test sample, the MBP method can borrow information 
from other genes in the same cluster by presenting a representative gene. When gene missing 
increases, the probability of the MBP method fails also increases. This especially happens when 
the cluster sizes are small and the cluster merging strategy is developed to avoid this problem. If 
a cluster size is smaller than the threshold δ, the cluster is merged into its nearest neighbor 
cluster to avoid the prediction failure due to clusters missing. The cluster sizes generated by K-
means clustering could be viewed as a random vector depending on the original data matrix.  A 
data mining is performed to explore the distribution of cluster sizes and in turn, generate 
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probability calculation under different number of genes, number of clusters and probability of 
missing genes.   
1.7.3 The MBP performance evaluation 
The newly developed MBP algorithm is tested on its prediction accuracy using publicly available 
microarray datasets. The prediction accuracy is assessed in both within-study and inter-studies 
scenarios and is compared with that of the GBP method using both univairate and multivariate 
feature selection methods. The MBP method is designed for model simplicity and robustness. 
The simplicity indicates that the method provides simple and easy use prediction model and the 
robustness indicates that the method can perform robust prediction with presence of gene 
missing and noise. Simulation studies are performed by randomly generating gene missing and 
noise in real gene expression profiles to evaluate the robustness of the MBP method. 
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2.0  EXPERIMENTAL DESIGN AND METHODOLOGY 
2.1 DATA SETS AND GENE MATCH 
Eight publicly available datasets were used to test the validity and adequacy of the MBP method 
(Table 2.1). Five prostate cancer datasets, Luo (Luo, Duggan et al. 2001), Yu (Yu, Landsittel et 
al. 2004), Welsh (Welsh, Sapinoso et al. 2001), Dhan (Dhanasekaran, Barrette et al. 2001),and 
Lap (Lapointe, Li et al. 2004) were downloaded from a public available web site. The malignant 
prostate cancer and its matched adjacent prostate tissue samples from Yu, Welsh, and Lap 
datasets, and the malignant prostate cancer and its matched donor samples from Luo and Dhan 
datasets were used for two sets of pair-wise cross-platform analyses. Three lung cancer data sets, 
Beer (Beer, Kardia et al. 2002), Bhat (Bhattacharjee, Richards et al. 2001), and Garber (Garber, 
Troyanskaya et al. 2001), were downloaded from publicly accessible information supporting the 
published manuscripts. Only the normal and the adenocarcinoma samples were used for analysis. 
All three datasets were from different platforms or different versions, and pair-wise inter-study 
analyses were performed.  
     All pair-wise inter-study analyses relied on matching genes between training data and test 
data. Entrez ID was used to match Affymetrix datasets using the R package “annotate” (Kuhn, 
Luthi-Carter et al. 2008), and a web-based match tool, MatchMiner, was used for cDNA datasets 
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(Bussey, Kane et al. 2003). The genes sharing the same Entrez ID was averaged for their 
expression. 
                                  Table 2.1  Datasets used in the study 
             
----------------------------------------------------------------------------------------------------------------------
Tumor Type        Dataset          Authors                           Platform                   Sample histology 
----------------------------------------------------------------------------------------------------------------------- 
Lung Cancer       Beer           Beer et al                      Affymetrix U95A             86 AC, 10 normal  
                            Bhat           Bhattacharjee et al       Affymetrix HG 6800      134 AC, 17 normal  
                            Garber       Garber et al                  cDNA                                39 AC,   5 normal 
 
Prostate Cancer  Luo             Luo et al                       cDNA                              16 PC,    9 donors 
                           Dhan           Dhanasekaran et al      cDNA                               14 PC,  19 donors 
 
                           Yu              Yu et al                         Affymetrix U95A            66 PC,  59 Adjacent  
                           Welsh         Welsh et al                   Affymetrix U95A             25 PC,    9 Adjacent  
                           Lap             Lapointe et al               cDNA                                62 PC,  41 Adjacent  
------------------------------------------------------------------------------------------------------------------------- 
 
2.2 DATA DESCRIPTION AND PREPROCESSING:  
Beer dataset The data was originally published in Nature Medicine 2002 by Beer et al (Beer, 
Kardia et al. 2002). The 86 lung adenocarcinoma samples were collected from the University of 
Michigan Hospital between May 1994 and July 2000 from 67 stage I and 19 stage III patients, 
and 10 non-neoplastic lung tissues were also obtained during that time. The total 96 samples 
were analyzed using Affymetrix HG6800 microarray chips. After the data preprocessing, 4467 
genes remained in the dataset.   
Bhat dataset The data was originally published in PNAS 2001 by Bhattacharjee et al 
(Bhattacharjee, Richards et al. 2001). The data used in the project was the subset of the total 203 
snap-frozen samples, including 134 lung adenocarcinoma samples and 17 normal lung 
specimens. The samples were collected from the Thoracic Oncology Tumor Bank at the Brigham 
  13
and Women’s Hospital/Dana–Farber Cancer Institute, Harvard University. Total 151 samples 
were analyzed using Affymetrix U95A microarray chips. After the data preprocessing, 4107 
genes remained in the dataset.   
Garber dataset The data was originally published in PNAS 2001 by Garber et al (Garber, 
Troyanskaya et al. 2001). The data included 39 lung adenocarcinoma samples and 5 normal lung 
specimens. Total 44 samples were analyzed using cDNA microarrays. After the data 
preprocessing, 3399 genes remained in the dataset.   
Luo dataset The data was originally published in Cancer Research 2001 by Luo et al (Luo, 
Duggan et al. 2001). The data included 16 prostate adenocarcinoma samples from Johns Hopkins 
Hospitals during October 1998 and March 2000, and 9 benign prostatic hyperplasia specimens 
from Johns Hopkins Hospital during February 1999 and November 2000. Total 25 samples were 
analyzed using cDNA microarrays. After the data preprocessing, 3673 genes remained in the 
dataset.   
Dhan dataset The data was originally published in Nature 2001 by Dhanasekaran et al 
(Dhanasekaran, Barrette et al. 2001). The data included 14 prostate adenocarcinoma samples 
from University of Michigan Prostate SPORE tumor bank and 19 noncancerous. Total 33 
samples were analyzed using cDNA microarrays. After the data preprocessing, 7784 genes 
remained in the dataset.   
Lap dataset: The data was originally published in PNAS 2004 by Lapointe et al (Lapointe, 
Li et al. 2004). The data included 62 primary prostate cancer samples and 41 matched normal 
prostate tissues from Stanford University, Karolinska Institute, and Johns Hopkins University. 
Total 33 samples were analyzed using cDNA microarrays. After the data preprocessing, 1735 
genes remained in the dataset.   
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Welsh dataset The data was originally published in Cancer Research 2001 by Welsh et al 
(Welsh, Sapinoso et al. 2001). The data included 25 primary prostate cancer samples and 9 
matched normal prostate tissues from University of Virginia. Total 33 samples were analyzed 
using Affymetrix U95A microarray chips. After the data preprocessing, 9494 genes remained in 
the dataset.   
Yu dataset The data was originally published in JCO 2004 by Yu et al(Yu, Landsittel et al. 
2004). The data included 66 primary prostate cancer samples and 59 matched normal prostate 
tissues. Total 125 samples were analyzed using Affymetrix U95A microarray chips. After the 
data preprocessing, 9109 genes remained in the dataset.   
All the data were preprocessed using standard data filtering by eliminating genes with low 
expressions and genes not varying sufficiently across the training samples. The data were 
standardized by first column-wise and then row-wise normalization by subtracting column or 
row means and dividing by the corresponding column or row standard deviations. 
2.3 NOTATIONS AND GENERAL CONCEPT 
Suppose a prediction model is to be constructed from a training study and will be applied to a 
test study. Let  be the gene set covered in the training study and  in the test study, where 
normally  if the training and test studies are of different microarray platforms. Denote 
by  the expression intensity matrix of the training study 
and , where g represents gene indexes and s are samples. For traditional 
GBP methods, gene sets covered in the training and test studies have to be identical so that the 
trG
teG
g ∈,
{ Gg ∈
teG
trG ≠
trgsx=
tegsx ,
{ trtrtr SsGD ∈,
tetete SsD ∈= ,
}
}
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prediction model can be applied across studies. The prediction model is usually constructed in 
the submatrix { }trtetrtrgstr SsGGgxD ∈∈= ,,~ ∩  and applied to { }tetetrtegste SsGGgxD ∈∈= ,,~ ∩ . As a 
result, the prediction model is not totally independent of the test study information. In the MBP 
approach, the gene set  in the training study is clustered into K clusters by K-means such that 
 and  for 
trG
tr φ=trjtri GG ∩ ikKktr GG 1== ∪ Kj ≤<≤1
tr
kG
. The prediction model will be constructed 
based on the K cluster modules, of the form , where  is the representative gene 
vector in cluster module . In this study, the “median gene” that has the smallest sum of 
distances to other genes in the cluster was used as the representative gene vector. Namely when 
) trkr,...,
tr
Kr,( 21 trtr rrF
∑ ∈ ••∈= trkGmtrkg minarg~ −trmtrkGg trgxx  and 2)trgstrms xx − ),( ~ trtr sgtrk Ssxr trk ∈=2 (Sstrgx tr= ∑ ∈•
tetr
k GG ∩=
trmx −• , .  For 
application to the test study, denote by  the genes in the k-th cluster module that 
appear in the test study. If , the representative gene vectors can be similarly 
calculated as  where 
te
kG
k∀
)
Gtek ≠
,( ~te sg sx tek
φ
teS∈tekr = ∑ ∈ ••∈ −= tektek Gg tegtemGmtek xxg minarg~  and 
2)temsx
2
(
Ss
tegtem xx te=− ∑ ∈••
),...,,( 21 teKtete rrrF
tegsx− . The proposed MBP model can then be applied to the test study 
by .  
2.4 ALGORITHM DEVELOPMENT 
The MBP algorithm was developed under the rationale that genes sharing similar expression 
profiles could be grouped together and that a representative gene can be selected from the group 
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of genes. The algorithm involved four major steps: gene clustering, cluster merging, cluster 
selection, and model construction. The MBP schema is shown in Figure 2.1. 
Gene clustering The processed data were clustered into K clusters by the classical K-means 
method (Hartigan and Wong 1979) or PW-K-means method (Tseng 2007). The clusters were 
defined as gene modules. Normally K = 100 or 150 was chosen.  
Module merging When the number of genes within a module was less than a given 
threshold δ, the small module was merged into its nearest-neighboring module based on the 
minimum distance between module centroids. The selection of δ was determined by a 
probabilistic model described below to avoid missing genes of the entire module in the test study 
with high probability. 
Module selection Although in the MBP approach, the number of features has been reduced 
to hundreds, the dimensionality is still high and proper feature (module) selection is needed to 
achieve better performance. Thus, both univariate and multivariate feature selection methods 
were explored. For univariate feature selection, the top k modules are selected according to their 
ranks of average absolute value of moderated t statistics (Tibshirani, Hastie et al. 2002), and the 
representative genes within each selected module were used to construct the prediction model. 
For multivariate feature selection methods, the module selection was embedded with the 
prediction model construction. 
Model construction The selected representative genes of the prediction module were used to 
fit the prediction models. For univariate feature selection methods, three classical classification 
methods included linear discrimination analysis (LDA) (Mardia, Kent et al. 1979), , k-nearest 
neighbor (KNN) (Dasarathy 1991), and supporting vector machine (SVM) (Cristianini and 
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Shawe-Taylor 2000) were examined. For multivariate feature selection, prediction analysis of 
microarray (PAM) (Tibshirani, Hastie et al. 2002) was explored.  
 
 
 
 
 
 
 
…
…Clustering Merging
Selection
Module
Test sample
Input
Output
Output
MBP
Classifier
Representative 
gene
 
 
 
 
Figure 2.1  Schema of the module based prediction (MBP) method: a microarray data with 
sizable samples is selected as training input for the MBP; then the genes are clustered into groups 
using unsupervised method based on the gene similarity, such as K-means correlation method; 
for those gene cluster sizes smaller than a threshold δ, the clusters are merged into their nearest 
neighbor; the clusters after merging are selected by moderate t statistics to form prediction 
modules which comprise of the prediction model as the output; for each module, a representative 
gene is selected based on the minimum sum of distance among the genes within the module; then 
the representative genes are used to predict outcome for a new test sample.        
 
The algorithm was implemented using R 2.7.1 (free software downloaded from www.r-
project.org). The MBP core algorithm was written using R program, however, some functions, 
such as K-means clustering, classifiers (LDA, KNN, SVM, PAM) were downloaded from R 
packages. The PW-K-means clustering program C code was provided by Dr. Tseng.     
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2.5 MINIMUM CLUSTER SIZE IN MODULE MERGING AND DISTRIBUTION 
DIAGNOSIS 
One of the motivations to develop the MBP method is to build a prediction model solely on the 
training data, independent of test data and portable across studies with different microarray 
platforms. A necessary condition for the MBP procedure to succeed is that the test study should 
contain one or more genes in each gene cluster module in order to calculate the representative 
gene vector in the prediction model. Below a simplified probabilistic model to estimate the 
smallest δ needed to achieve the goal is provided. Assume π is the probability for a gene in the 
training study to be missing in the test study and that gene missing is independent of each other. 
The probability that the MBP method obtains no less than N genes in each of the K modules in 
the test study is 
( )
∏ ∑
=
−
=
−
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −⋅⋅⎟⎟⎠
⎞
⎜⎜⎝
⎛−=
=
K
k
N
n
nnGn
tr
k
KK
tr
k
n
Gn
GGp
1
1
0
)( )1(
)(
1
~
study test in genesN   thanless has module noPr)
~
,(~
ππ
π
  (1) 
where ( )(,),( )~ 1 trKtrK GnGnG "=
%99~ >p
 and  is the number of genes in cluster . In this paper, we 
require  and N = 3. The probability calculation depends only on the gene missing 
probability π and the module sizes, . In the data analyses of the eight data sets used in this 
paper, we found that the cluster sizes generated by K-means clustering follow multinomial 
distributions very well, i.e. 
)( trkGn
)( trkGn
tr
kG
( ) ( )KK ,GnlMultinomiaGn trtrKK 1,1),(~)(,Gn tr(G ),~ 1= "" . (see QQ-
plots in Figure 3.1). Thus the probability of each module in test study to have no less than N 
genes becomes 
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~)~(study) test in genesN   thanless has module (no
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π
π
              (2) 
To estimate the minimal δ required in the module merge procedure, the following simulation 
to calculate the probability was performed such that each module in the test study has no less 
than N genes after δ-merge: 
1. Suppose , K, π, δ are given. Simulate )( trGn KG~  from ( )KKGnlMultinomia tr 1,,1),( " . 
2. Given δ, merge clusters with less than δ genes into a random cluster. Suppose the resulting 
cluster sizes become ''
~
KG (K′≤K). 
3. Compute the conditional probability, )'
~
,(~ 'KGp π  from equation (1). 
4. Repeat 1-3 for B times (B=1,000 in this study). The probability of successful application to the 
test study can be estimated by 
∑
=
=
B
b
K
b
tr
Gp
KGnp
1
'
)( )'~,(~
B
1=
merge)-|study test in genesN   thanless has module P(no),,),((
π
δδπ
(3) 
5. Find the smallest δ such that . 99.0),,),(( ≥δπKGnp tr
The advantage of the probabilistic model is that the estimation of minimal δ only depends on the 
total number of genes in the training data ( ), the number of clusters K used in K-means 
and the probability of gene missing in the test study. It does not depend on the observed data and 
a table can be computed for a rapid decision in future applications. For example, when 4,000 
genes are analyzed in the training study, Kmeans clustering generated K = 100 modules and one 
expects π = 50% gene missing probability in the test study, δ ≥ 3  was required in δ-merge to 
)( trGn
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guarantee successful application of the MBP in inter-study prediction with 99% probability (see 
Table 3.1 in the result section). 
2.6 CLASSIFICATION METHODS 
In this study, binary outcome prediction or classification was the main focus; however, the 
method can be extended to other outcome predictions, such as those for time to event data. To 
evaluate the MBP performance, four commonly used classifiers, LDA, KNN, PAM and SVM 
were chosen for univairate or multivariate selections. For univariate selection, the features were 
chosen by selecting top k clusters for the MBP or top q individual genes for the GBP based on 
moderate t statistics; whereas for multivariate selection, the features were chosen by considering 
correlations among genes and minimizing error rate using the two state-of-the-art methods, PAM 
and Recursive-SVM (Zhang, Lu et al. 2006).   
Linear discriminate Analysis (LDA) Originally conceptualized by RA Fisher and 
developed by others (Fisher 1936; Mardia, Kent et al. 1979), LDA is a very popular statistical 
classification method, which identifies linear combinations of features that accurately separate 
two or more classes of events. The method also is used for data dimension reduction. In this 
study, LDA was used for classification purposes.   
K-nearest neighbor (KNN) KNN is a simple machine learning method to classify the events 
based on the majority vote of its neighbors (Dasarathy 1991). It is very useful for features in 
multidimensional space. KNN was used for classification purposes here. 
Support vector machine (SVM) SVM is a supervised machine learning method that identify 
the classes by separating hyperplanes, which maximizes the margin between two classes 
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(Cristianini and Shawe-Taylor 2000). Generally, SVM is used to classify two groups of data, but 
it can be extended to separate more than two groups of data (Hsu and Lin 2002). In this study, 
binary SVM classification method was used to compare results among different classifiers.  
Nearest centroid This method was used as a special case when no shrinkage operation 
involved for feature selection in PAM (Tibshirani, Hastie et al. 2002) and marked as PAM-U or 
PAM for PAM univariate feature selection.  
2.7 FEATURE SELECTION METHODS 
Two feature selection approaches were used to select prediction modules for the MBP, i.e. 
univairate and multivariate feature selections. For univariate approach, once the genes in training 
set are grouped in K clusters, the top k clusters are selected based on the absolute value of 
moderate t statistics to form the prediction modules; whereas for multivariate approach, the 
prediction modules are selected by the following two feature methods from K clusters.  
Prediction analysis for microarrays (PAM) Published in 2002 (Tibshirani, Hastie et al. 
2002), PAM has become a very popular method for gene classification and prediction. The 
unique part of the PAM is its centroid shrunken algorithm (Tibshirani, Hastie et al. 2002). Unlike 
LDA, KNN, and SVM, PAM was used for both feature selection and classification in this study.  
Recursive supporting vector machine (R-SVM) R-SVM was developed for genes 
classification of noisy data. Similar method was reported in machine learning 2002 by Guyon et 
al (Guyon, Weston et al. 2002) using SVM recursive feature elimination or SVM-RFE to select 
gene features robust to outliers. However, according to Zhang et al, R-SVM was better than 
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SVM-RFE in regarding to robustness to noise (Zhang, Lu et al. 2006). R-SVM was used as a 
multivariate selection method in the study.   
2.8 EVALUATION AND SIMULATION 
Prediction accuracy versus prediction performance index In common practice, prediction 
performance is evaluated by overall accuracy, calculated as the correctly predicted number of 
subjects divided by total number of subjects tested. Sometimes, the accuracy may misinterpret 
the prediction performance when samples are imbalanced between the two groups of subjects, 
e.g. if a hundred of subjects are tested, ninety five of them are cancer patients and five of them 
are normal. For a useless predictor, all subjects are classified into the cancer group and the 
prediction accuracy is still 95%. To avoid this problem, besides prediction accuracy, a prediction 
performance index (PPI), computed as the average of sensitivity and specificity, was used to 
evaluate the prediction performance. As for previous example, PPI is 50%.   
The MBP versus the GBP within study prediction  Prediction performance was assessed 
for every dataset using a leave-one-out cross validation (LOOCV) approach (Kohavi 1995). 
Since there were random factors during K-means in the MBP method, the LOOCV was run thirty 
or hundred times and used LDA, KNN, and SVM as the classifiers. The means and standard 
deviations of accuracies were calculated and compared with the accuracies obtained from the 
traditional GBP method based on moderate t statistics feature selection and PAM method.  
The MBP versus the GBP inter-study prediction Cross-platform prediction was performed 
by the standard MBP algorithm stated above. The test data used in the pair wise inter-study 
analyses were three lung cancer datasets, three prostate cancer datasets matched with adjacent 
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tissues as controls, and two prostate cancer datasets using donors’ samples as controls. The 
prediction accuracies and PPI were calculated based on three classifiers, LDA, KNN, and SVM. 
The results were compared with those of the GBP method, which only used genes common to 
both training and test datasets. PAM classification method with univariate and multivariate 
feature selections were also evaluated. 
Simulation with varying gene variability To determine whether using gene cluster 
information would create a model that was robust even when gene noise was present, white noise 
was randomly added to the Luo dataset. The noise followed a Gaussian distribution with mean μ 
= 0 and standard deviationσ . The magnitude of noise was determined by size of σ, and the 
range of noise added was based various different proportions of noise ( p ). The prediction 
accuracies were evaluated by the LOOCV approach across different σs and different ps and were 
compared with their counterparts from the GBP methods. 
Simulation with gene mismatches in cross-platform scenario The robustness to missing 
genes was evaluated by randomly splitting the Luo dataset into a training dataset and a test 
dataset by a 1:1 ratio, and serial proportions of genes were randomly deleted from the training 
and test dataset to create missing genes. The prediction accuracies and prediction successful rate 
(PSR), defined as number of successful predictions divided by the total number of prediction 
tests attempted when genes used for prediction are missing in test set, were compared between 
the MBP method and the GBP method using LDA, KNN, and SVM classifiers.   
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3.0  RESULTS 
3.1 DISTRIBUTION OF CLUSTER SIZE 
In order to estimate minimum cluster size, δ, one needs to know the distribution of the cluster 
size generated by K-means’ method. Since K-means’ clusters were randomly generated, the 
cluster size, was considered as a random variable, which might affect the prediction or 
classification accuracy and stability for approaches involving clustering as the data reduction 
method. usually depends on,
tr
kG
tr
kG trG K , and individual dataset. To have a good estimate of δ, it is 
essential for one to estimate the distribution of . Both conditional Poisson and multinomial 
distributions were tested to fit the distribution of . The distribution was estimated using the 
eight datasets under either Poisson or multinomial conditions by fitting QQ-plots. The results 
showed that the Poisson fits were not good (data not shown), but the eight datasets fitted well 
under multinomial assumptions (Figure 3.1). Determination of distribution provided useful 
information for estimation of  δ. 
tr
kG
tr
kG
tr
kG
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3.2 ESTIMATION OF MINIMUM CLUSTER SIZE 
As a key parameter of the MBP model, δ was used to control or minimize prediction failure 
caused by missing genes when genes in a model built on training set do not exist in a test set. 
When a cluster size was smaller than δ, the cluster was merged into its nearest cluster to 
minimize the probability of prediction failure. A smaller leads to a higher probability of 
prediction failure. It is crucial to estimate δ given the proportion of genes missing in test set, π, 
and the probability of successful prediction, α (considered acceptable when α = 99%).  
tr
kG
tr
kG
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Figure 3.1 QQ-plots of observed cluster size versus theoretical cluster size generated 
according to multinomial distributions: X axis represents cluster size generated by K-means 
clustering method and Y axis represents cluster size simulated by multinomial distribution. 
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The simulated results were listed in Table 3.1 ( B =1000). The results showed that the threshold δ 
were higher when K , π , and α increased, whereas decreased. Also cluster sizes after  trG
Table 3.1 Simulated results for estimation of δ and 'K  (B=1000, N=3) 
----------------------------------------------------------------------------------------------------------- 
                                                                                     π            
)( trGn         K            ------------------------------------------------------------------------------- 
                                    0.2             0.3             0.4               0.5              0.6               0.7 
------------------------------------------------------------------------------------------------------------ 
2000       100          1 (100)        1 (100)       1 (100)      15 (  91)      20 (  63)      25 (  43) 
2000       125          1 (125)        8 (124)     12 (111)      16 (  78)      19 (  58)      25 (  42) 
2000       150          7 (147)      10 (130)     13 (  98)      16 (  71)      19 (  59)      26 (  44) 
2000       175          8 (156)      10 (130)     13 (  91)      15 (  76)      19 (  61)      26 (  45) 
2000       200          8 (161)      10 (127)     12 (  99)      15 (  76)      19 (  61)      26 (  43) 
 
3000       100          1 (100)        1 (100)       1 (100)        1 (100)      12 (100)      29 (  67) 
3000       125          1 (125)        1 (125)       1 (125)      12 (125)      21 (  98)      27 (  61) 
3000       150          1 (150)        1 (150)       9 (150)      16 (129)      21 (  85)      26 (  61) 
3000       175          1 (175)        7 (175)     12 (162)      17 (111)      20 (  85)      26 (  65) 
3000       200          6 (200)      10 (187)     13 (154)      16 (114)      20 (  82)      27 (  64) 
 
4000       100          1 (100)        1 (100)       1 (100)        1 (100)        1 (100)      21 (100) 
4000       125          1 (125)        1 (125)       1 (125)        1 (125)        1 (125)      30 (  89) 
4000       150          1 (150)        1 (150)       1 (150)        1 (150)      22 (128)      29 (  78) 
4000       175          1 (175)        1 (175)       1 (175)      15 (170)      22 (117)      28 (  76) 
4000       200          1 (200)        1 (200)     11 (198)      17 (161)      22 (105)      27 (  79) 
 
5000       100          1 (100)        1 (100)       1 (100)        1 (100)        1 (100)        1 (100) 
5000       125          1 (125)        1 (125)       1 (125)        1 (125)        1 (125)      27 (124) 
5000       150          1 (150)        1 (150)       1 (150)        1 (150)        1 (150)      31 (109) 
5000       175          1 (175)        1 (175)       1 (175)        1 (175)      21 (165)      30 (  98) 
5000       200          1 (200)        1 (200)       1 (200)      13 (200)      22 (157)      29 (  94) 
------------------------------------------------------------------------------------------------------------ 
  
merging, 'K were estimated shown in parentheses in Table 3.1. This table provided a reference 
when the threshold was set up for cluster merging. Meanwhile, based on the simulation results, 
as shown in Table 3.2, δ for each pair of training and test datasets was estimated, given K = 100, 
α = 99%, and as indicated in parentheses, π was calculated based on the number of matched 
intersection genes in both training and test data sets divided by the number of genes in training 
data sets, and δ was estimated based on the multinomial distribution of cluster size (Table 3.2).   
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The results showed that gene mismatching between the training datasets and test datasets varied 
from 36% to 97%. The following evaluations of the MBP and the GBP performances were based 
on the data mismatching scenarios.   
 
                  Table 3.2  Common gene cross platform data with (π, δ) 
---------------------------------------------------------------------------------------------------------------------------
                                                                              Test    
 Training       ----------------------------------------------------------------------------------------------------------- 
                      Beer          Bhat          Garber          Luo          Dhan          Welsh           Yu          Lap  
--------------------------------------------------------------------------------------------------------------------------- 
Beer              4467          2493            1594             -               -                    -                  -            -  
                   (0.00, 1)     (0.44,1)       (0.64,1) 
 
Bhat             2493          4107            1493              -               -                   -                  -             -           
                  (0.39, 1)    (0.00, 1)      (0.64, 1)  
 
Garber        1594          1493             3399              -               -                   -                  -             -   
                  (0.53, 1)   (0.56, 1)       (0.00, 1)   
 
 Luo               -                -                   -              3673         2352               -                 -              -  
                                                                         (0.00, 1)    (0.36, 1)   
 
 Dhan            -                 -                  -               2352         7784               -                  -             - 
                                                                         (0.70, 1)    (0.00,1)     
 
Welsh           -                 -                  -                  -               -              9494          2521          356 
                                                                                                           (0.00,1)    (0.73, 1)   (0.96, 100)     
  
Yu                -                 -                  -                  -               -               2521         9109           295 
                                                                                                           (0.72, 1)   (0.00, 1)    (0.97, 100) 
 
Lap              -                 -                   -                 -               -                356            295           1735 
                                                                                                           (0.79, 43)  (0.83, 34)   (0.00, 1)           
----------------------------------------------------------------------------------------------------------------------------  
3.3 PREDICTION ACCURACIES WITHIN STUDY 
The purpose of the analysis is to test the assumption of no significant loss of predictive power 
regarding to the prediction accuracy using the MBP method within a study. We may or may not 
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expect an increased prediction accuracy of the MBP. Given 100=K , k =10, 20, 30 and δ = 10 
for MBP, and selected top differentiated genes of 10, 20, and 30 for the GBP, the prediction 
accuracies of the MBP versus those of the GBP using three classifiers, LDA, KNN, and SVM 
across eight cancer datasets were computed using LOOCV, as shown in Figure 3.2, given the 
condition that if there was at least one gene matched in the test set, i.e. N ≥ 1.  The results 
showed that the prediction accuracies were classifier, number of selected features, and data 
dependent; however, there was no evidence showing that either the GBP or the MBP 
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Figure 3.2 Within study prediction accuracies between the MBP and the GBP across eight 
cancer datasets: The MBP prediction accuracies were compared with those of the GBP within 
eight datasets using LOOCV approach. The parameters were set for MBP as K=100, k =10, 20, 
and 30, N≥1, and δ=10 and the parameters was set for the GBP as q =10, 20, and 30.  
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method yielded better prediction accuracy one way or another despite fluctuations of the 
prediction accuracies across different datasets and different classifiers, indicating that the 
performance of these two methods was indistinguishable. Further, we changed parameters from 
N ≥ 1 to N ≥ 3 and δ = 10 to δ = 20, hoping it would yield more stable results. As shown in 
Figure 3.3, the results were similar as in Figure 3.2, but with smaller standard deviations after 30 
repeated tests. The results indicated that no significant loss of predictive power using the MBP 
within a study across the eight cancer datasets.  
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Figure 3.3  Within study prediction accuracies between the MBP and the GBP across six 
cancer datasets: The MBP prediction accuracies were compared with those of the GBP within 
six datasets using LOOCV approach. The parameters were set for the MBP as K=100 and 150, k 
=10, 20, and 30, N ≥ 3, and δ=10 and the parameters was set for the GBP as q = 10, 20, and 30.  
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3.4 PREDICTION ACCURACIES INTER-STUDIES 
Since prediction accuracies were indistinguishable between the two methods in within studies, 
the MBP performance was then tested on datasets in inter-studies and compared with the GBP 
regarding to prediction accuracy and PPI. There were three sets of inter-study evaluations: one 
set of lung cancer data, including Beer, Bhat, and Garber, and two sets of prostate cancer data, 
i.e. one set with donors as control including Luo and Dhan and the other set with adjacent tissues 
as control, including Lap, Welsh, and Yu. The three sets of pair-wise platform comparisons were 
shown in Table 3.2. Each dataset within the three sets served as training data in turns and tested 
on the other dataset. The number of genes in each training dataset and the number of common 
genes to each testing pair dataset were listed in Table 3.2. The gene missing rate varied from 
36% to 97% (Table 3.2). Given , =10, 20, 30 and δ =10 for the MBP and selected top 
differentiated genes of 10, 20, and 30 for the GBP, the prediction accuracies of the MBP versus 
those of the GBP using three classifiers, LDA, KNN, and SVM across six pair-wise inter-study 
cancer datasets were computed, as shown in Figure 3.4. Given the condition of N ≥ 1, the results 
showed that the prediction accuracies were classifier, number of selected features, and data 
dependent; however, there was no evidence showing that neither the GBP nor the MBP method 
performed better than the other one despite fluctuations of the prediction accuracies across 
different datasets and different classifiers, indicating that the performance of these two methods 
was indistinguishable. Note that, the GBP inter-study predictions were based on intersection 
genes or common genes of pair-wise inter-study datasets, otherwise, the prediction failed due to 
gene mismatching in the test sets, indicating that the prediction model from the training set is not 
100=K k
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entirely independent from the test set and varies greatly when the test data set changes. The MBP 
method, however, does not have this issue.  
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Figure 3.4 Pair-wise inter-study prediction accuracies between the MBP and the GBP: The 
MBP prediction accuracies were compared with those of the GBP among ten pair-wise inter-
study datasets. The parameters were set for the MBP as K=100, k =10, 20, and 30, N ≥1, and 
δ=10 and the parameters was set for the GBP as q = 10, 20, and 30. Three classifiers were used 
for the comparison, LDA, KNN, and SVM. 
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Similarly as within study evaluation, the parameters were changed from N ≥ 1 to N ≥ 3 and δ =  
10 to δ = 20 to evaluate the MBP performance, compared with the GBP using intersection genes. 
As shown in Figure 3.5 and Figure 3.6, the results were similar as in Figure 3.4, but with smaller 
standard deviations after 100 repeated tests.  
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Figure 3.5 Pair-wise inter-study prediction accuracies between the MBP and the GBP: The 
MBP prediction accuracies were compared with those of the GBP among six pair-wise lung 
cancer inter-study datasets. The parameters were set for the MBP as K=100 and 150, k =10 and 
20, N ≥3, and δ=20 and the parameters was set for the GBP as q =10 and 20. Four classifiers 
were used for the comparison, LDA, KNN, SVM and PAM. 
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Figure 3.6 Pair-wise inter-study prediction accuracies between the MBP and the GBP: The 
MBP prediction accuracies were compared with those of the GBP among six pair-wise prostate 
cancer inter-study datasets. The parameters were set for the MBP as K=100 and 150, k =10 and 
20, N ≥3, and δ=20 and the parameters was set for the GBP as q =10 and 20. Four classifiers 
were used for the comparison, LDA, KNN, SVM and PAM. 
 
Noticed that three lung cancer datasets and two prostate cancer datasets, Luo and Welsh, used in 
the analyses were unbalanced between the tumor and control groups, we used PPI to evaluate the 
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MBP performance in addition to prediction accuracy shown in Figures 3.4, 3.5, and 3.6, to avoid 
inflated prediction accuracy. As shown in Figure 3.7, PPI was generally smaller than the  
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Figure 3.7   Pair-wise inter-study PPI between the MBP and the GBP: The MBP PPI was 
compared with that of the GBP among six pair-wise lung cancer inter-study datasets. The 
parameters were set for the MBP as K=100 and 150, k =10 and 20, N ≥3, and δ=20 and the 
parameters was set for the GBP as q =10 and 20. Four classifiers were used for the comparison, 
LDA, KNN, SVM and PAM. 
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 prediction accuracy shown in Figure 3.5 and showed greater variations among four classifiers 
across six pair-wise lung cancer datasets, especially, when Garber was involved in the pair-wise 
inter-study analyses. The GBP method was more sensitive to the accuracy inflation than that of 
the MBP method; however, the trend of the predictive power between the MBP and the GBP did 
not vary much when PPI or the accuracy was used in the performance evaluation. Similar results  
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Figure 3.8 Pair-wise inter-study PPI between the MBP and the GBP: The MBP PPI were 
compared with those of the GBP among four pair-wise prostate cancer inter-study datasets. The 
parameters were set for the MBP as K=100 and 150, k =10 and 20, N ≥3, and δ=20 and the 
parameters was set for the GBP as q =10 and 20. Four classifiers were used for the comparison, 
LDA, KNN, SVM and PAM. 
 
were generated using four prostate cancer datasets. As shown in Figure 3.8, the trend of the 
predictive power between the MBP and the GBP was consistent using both PPI and the accuracy 
  36
across four pair-wise prostate cancer inter-studies. The results suggest that the regular accuracy 
should be cautiously used when testing data are unbalanced and PPI is robust to the data 
unbalance. However, the discrepancy between the accuracy and PPI did not affect the results 
regarding to the comparison of predictive performance between the MBP and the GBP.     
3.5 ROBUSTNESS OF THE MBP TO MEASUREMENT VARIABILITY 
To determine the stability of the prediction accuracy using the MBP method, white noise was 
simulated and added to the Luo dataset. The prediction accuracies of the MBP and the GBP were 
evaluated based on the data with the white noise, using LOOCV approach and LDA, KNN, and 
SVM classifiers. The noise was added according to ),0( σN at serial proportions of 10%,  
20%, 50% and 70% with 0, 0.1σ, 0.5σ and 1.0σ, respectively. The prediction accuracies of the 
MBP method were quite stable across the noise added to the data (Figure 3.9 panels A-C), 
whereas the prediction accuracies from the GBP method were unstable when up to 0.5σ of noise 
was added (Figure 3.9 panel D). As for classifiers, LDA was more robust to noises than the other 
two classifiers, KNN and SVM. The standard errors were smaller when δ = 20 and N ≥3 were 
used than those when δ = 10 and N ≥1 were used. However, the pattern of MBP robust to the 
noise did vary from K and δ. The simulated results supported the hypothesis that the MBP was 
robust to gene noise. 
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Figure 3.9 Prediction accuracies between the MBP and the GBP after addition of white 
noise: The white noises with a Gaussian distribution of mean zero and standard deviation of 0, 
0.1, 0.5, and 1.0 fold of standard deviation, sigma, derived from the Luo dataset were added to 
the Luo dataset (3673 genes). The prediction accuracies of the MBP and the GBP were evaluated 
using LOOCV approach and three classifiers, LDA, KNN, and SVM. The prediction accuracies 
using the MBP method with gene noise were assessed by selecting K=100, k = 10, N ≥1 and δ 
=10 (panel A), or K=100, k = 10, N ≥3 and δ =20 (panel B), or K=150, k = 10, N ≥3 and δ =20 
(panel C); and the prediction accuracies using GBP method with gene noise were assessed by 
selecting q =10 (panel D). X axis represents percentage of genes with noise across three 
classifiers and Y axis represents prediction accuracy performances of different classifiers and 
amount of noise added. The tests were repeated 30 times and average of accuracies were 
calculated and represented as mean±SE.    
3.6 ROBUSTNESS OF THE MBP TO GENE MISMATCHING 
It is common that the pattern of a particular gene behaves differently across platforms due to 
different probe sequence selection in the platforms. Many genes appearing in one platform may 
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be missing in another, causing difficulties in applying the GBP method to inter-platform 
predictions. To evaluate whether the MBP method is robust when genes are missing in the test 
data, the prediction accuracies were evaluated by splitting an array dataset, Luo, into a training 
set and a test set and randomly deleting genes from both training and test set at different 
proportions (π), from 10% to 70% of genes deleted. The procedure was repeated 100 times and  
the model PSR were counted and tabulated in Table 3.3. The results showed that the MBP 
method could tolerate genes missing, but the GBP method was very sensitive to the missing 
genes and the prediction accuracies of the MBP method were stable across the proportions of 
missing genes (Figure 3.10) using LDA and KNN classifiers, indicating that the borrowed 
information in the MBP was reliable.  The simulated results supported the hypothesis that the 
MBP was robust to gene missing. 
 
             Table 3.3  PSR at gene difference of training and test sets     
        
------------------------------------------------------------------------------------------------------ 
                                                                             Test     (π )  
Method    Training (π)      --------------------------------------------------------------------- 
                                              0.1        0.2      0.3       0.4       0.5       0.6       0.7        
------------------------------------------------------------------------------------------------------ 
MBP                0.1               1.00     1.00     1.00     1.00     1.00     1.00     1.00      
                         0.2               1.00     1.00     1.00     1.00     1.00     1.00     1.00      
                         0.3               1.00     1.00     1.00     1.00     1.00     1.00     1.00      
                         0.4               1.00     1.00     1.00     1.00     1.00     1.00     1.00      
                         0.5               1.00     1.00     1.00     1.00     1.00     1.00     0.97      
                         0.6               1.00     1.00     1.00     1.00     1.00     1.00     0.99      
                         0.7               1.00     1.00     1.00     1.00     0.99     1.00     0.93      
 
 
GBP                 0.1               0.33     0.10     0.01     0.00     0.00     0.00     0.00      
                         0.2               0.40     0.09     0.07     0.01     0.01     0.00     0.00      
                         0.3               0.33     0.10     0.01     0.01     0.00     0.00     0.00      
                         0.4               0.43     0.11     0.01     0.01     0.00     0.00     0.00      
                         0.5               0.42     0.14     0.04     0.01     0.00     0.00     0.00      
                         0.6               0.36     0.14     0.01     0.01     0.00     0.00     0.00      
                         0.7               0.30     0.15     0.01     0.01     0.00     0.00     0.00      
------------------------------------------------------------------------------------------------------ 
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Figure 3.10  The MBP robust to gene missing: Percentage of successful prediction of the MBP 
versus the GBP using Luo data set with 3673 genes and K=100(panel A); Prediction accuracies 
using the MBP method with gene missing: two classifiers, LDA and KNN were used to assess 
the prediction accuracies by selecting k = 10 (panel B). And X axis represents percentage of 
genes deleted from test set given each classifier and Y axis represents performance of different 
classifiers. The tests were repeated 100 times and average of accuracies were calculated and 
represented as mean±SE.    
3.7 THE MBP PERFORMANCE WITH MULTIVARIATE FEATURE SELECTIONS  
From the above results, the MBP showed clear advantages over the GBP method with respect to 
prediction robustness; however, the feature selections were based on univariate method, i.e. 
moderate t statistics, to build the prediction models. To modify the feature selection to more 
sophisticated feature selection methods by considering interaction among the genes, two widely 
used multivariate feature selection methods, PAM and R-SVM, were used to evaluate prediction 
performances between the MBP and the GBP, and to assess the prediction performances between 
the multivariate and univariate feature selections as well. The prediction results using PAM were 
shown in Figure 3.11 Given or , and 100=K 150 10=k , and 20=δ  for the MBP, the average 
prediction accuracies of twelve cross-platform data analyses were compared between the MBP 
and the GBP using multivariate PAM (Panels A and B) and the average prediction accuracies 
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were also compared between univariate and multivariate feature selections(Panels C and D). As 
for the GBP, the common genes used were in both training and 
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Figure 3.11 The MBP performance using multivariate PAM: In order to select features by 
considering selection error rate and the correlations among the representative genes of K (100 or 
150) a multivariate PAM was used to evaluate the MBP performance compared with the GBP; 
meanwhile, the multivariate and univariate performances were assessed between the MBP and 
the GBP across three lung cancer datasets and five prostate cancer datasets in inter-study 
scenarios. Panels A and B show the performances between the MBP and the GBP of six pair-
wise inter-studies of lung cancer datasets (panel A) and of six pair-wise inter-studies of prostate 
cancer datasets (panel B); whereas, panels C and D show the performances between multivariate 
and univariate selections using the MBP and the GBP of six pair-wise inter-studies of lung 
cancer datasets (panel C) and of six pair-wise inter-studies of prostate cancer datasets (panel D). 
The curves in different colors represent average prediction accuracies of 30 repeated tests for six 
pair-wise lung cancer datasets showing in panel A and panel C and six pair-wise prostate cancer 
datasets showing in panel B and panel D.  Parameters set up for the MBP were K=100 and 150, k 
=10 for univariate selection, δ =20 and N ≥3, while, univariate selection for the GBP was set up 
for q =10. MV stands for multivariate selection and UV stands for univariate selection.  
 
test sets known as intersection genes, but predictions failed when all genes in the training sets 
were used to build prediction models. From Figure 3.11 A-B, the results showed that there was 
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no significant difference of the prediction accuracies between using the MBP and using the GBP, 
across six pair-wise lung cancer data tests (Panel A) and six pair-wise prostate cancer data tests 
(Panel B), and from Figure 3.11 C-D, the prediction performances between the univariate and 
multivariate feature selection approaches were quite similar when the MBP was used at 100=K , 
whereas, the performances between the two feature selection approaches were data dependent 
when the GBP or MBP at was used.  Similar results were observed using another 150=K
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Figure 3.12 The MBP performance using multivariate R-SVM: In order to select features by 
considering selection error rate and the correlations among the representative genes of K (100) a 
multivariate R-SVM was used to evaluate the MBP performance compared with the GBP; 
meanwhile, the multivariate and univariate performances were assessed between the MBP and 
the GBP across three lung cancer datasets and four prostate cancer datasets in inter-study 
scenarios. Panels A and B show the performances between the MBP and the GBP of six pair-
wise inter-studies of lung cancer datasets (panel A) and of four pair-wise inter-studies of prostate 
cancer datasets (panel B); whereas, panels C and D show the performances between multivariate 
and univariate selections using the MBP of six pair-wise inter-studies of lung cancer datasets 
(panel C) and of four pair-wise inter-studies of prostate cancer datasets (panel D). The curves in 
different colors represent average prediction accuracies of 30 repeated tests for six pair-wise lung 
cancer datasets showing in panel A and panel C and four pair-wise prostate cancer datasets 
showing in panel B and panel D.  Parameters set up for the MBP were K=100, k =10 for 
univariate selection, δ =20 and N ≥3, while, univariate selection for the GBP was set up for q 
=10. MV stands for multivariate selection and UV stands for univariate selection.  
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multivariate feature selection method, R-SVM. As shown in Figure 3.12, the prediction 
performances of MBP and GBP were data dependent (Panels A and B). As for the performances 
between the univariate and the multivariate feature selections using R-SVM were quite similar, 
however, also data dependent (Panels C and D). The results suggest that the prediction 
performances between the MBP and the GBP are indistinguishable and that there was no 
evidence that the multivariate feature selection method outperformed the univairate method 
using both PAM and R-SVM, indicating no significant loss of predictive power using the MBP 
method. Lai et al reported that the classification performance was indistinguishable between 
using univariate and multivariate feature selection methods (Lai, Reinders et al. 2006)   
3.8 THE MBP PERFORMANCE USING PW-K-MEANS CLUSTERING METHOD  
One of the factors might affect the MBP performance is the quality of the clusters. Given K-
means method forces all genes into K clusters resulting in outlier genes in certain clusters, PW-
K-means method was developed to eliminating the gene outliers out of clusters and made the 
clusters tight by adding penalty weights when genes were assigned to certain clusters, such that 
the cluster quality would be improved (Tseng 2007). To evaluate whether such a procedure 
improved the MBP performance, PW-K-means clustering was used to replace K-means 
clustering to group genes for the MBP and the results using PW-K-means method was compared 
with those using K-means method. As shown in Figure 3.13, the results showed that using PW-
K-means clustering did not improve the MBP performance given a range of penalty parameter 
lambda (0.3, 0.5, 0.7, 0.9, 1.1 and 999) compared with using K-means method across four 
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prostate cancer and two ling cancer datasets, indicating that the MBP method was robust enough 
to overcome gene noise caused cluster outliers. In this section, we also used PPI to evaluate the  
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Figure 3.13 The MBP prediction accuracy using PW-K-means clustering as gene grouping 
method: In order to improve quality of gene clusters by eliminating noise genes PW-K-means 
clustering method was used to group genes based on their expression similarities. The 
elimination of noise genes was determined by a parameter lambda and the smaller lambda would 
eliminate more noise genes. Panels A-D are the MBP inter-study performances across the four 
prostate cancer datasets and panels E-F are the MBP inter-study performances across two lung 
cancer datasets. The curves in different colors represent average prediction accuracies of 30 
repeated tests for four univariate classifiers (Dark blue: KNN, Red: LDA, Black: SVM, Magenta: 
PAM-UV)) and a multivariate classifier (Brown: PAM-MV). Variations from multiple tests are 
represented as standard errors (error bars). X axis represents a range of lambdas set for PW-K-
means method and a K-means method. Parameters set up for the MBP were K=100, k =10, δ =20 
and N ≥3. 
 
MBP performance in addition to prediction accuracy to avoid inflated prediction accuracy. As 
shown in Figure 3.14, PPI was generally smaller than the prediction accuracy shown in Figure 
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3.13 across four prostate cancer and two lung cancer datasets and showed greater variations 
among four classifiers; however, the trend of the predictive power between using the prediction 
accuracy and PPI did not vary across penalty parameters, lambda used.  
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Figure 3.14 The MBP PPI using PW-K-means clustering as gene grouping method: In order 
to improve quality of gene clusters by eliminating noise genes PW-K-means clustering method 
was used to group genes based on their expression similarities. The elimination of noise genes 
was determined by a parameter lambda and the smaller lambda would eliminate more noise 
genes. Panels A-D are the MBP inter-study performances across the four prostate cancer datasets 
and panels E-F are the MBP inter-study performances across two lung cancer datasets. The 
curves in different colors represent average prediction accuracies of 30 repeated tests for four 
univariate classifiers (Dark blue: KNN, Red: LDA, Black: SVM, Magenta: PAM-UV)) and a 
multivariate classifier (Brown: PAM-MV). Variations from multiple tests are represented as 
standard errors (error bars). X axis represents a range of lambdas set for PW-K-means method 
and a K-means method. Parameters set up for the MBP were K=100, k =10, δ =20 and N ≥3. 
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3.9 THE MBP PERFORMANCE USING MEDIAN GENE VERSUS SAMPLE 
MEDIAN   
To reduce prediction module dimension from  to sGtrk ×' s×1 vector to fit prediction model, we 
proposed a new metric, a representative gene or a median gene for each module, instead of 
commonly used sample mean or sample median by computing average point for each sample. 
The advantage of using the median gene is to identify an actual gene with biological meaning for 
the MBP method; however, the predictive power of using the median gene needs to be justified 
by comparing the predictive accuracies between the median gene and the sample median. Table 
3.4 shows that the averages of prediction accuracies and standard errors from 100 repeated 
LOOCV of three lung cancer datasets, respectively. The results demonstrated that the predictive 
power was equivalent between using the median gene and the sample median using LDA. The 
averages of prediction accuracy of using the two methods were 0.93 and 0.93, respectively, 
indicating that using the median gene is feasible.  
 
Table 3.4   Accuracies of median gene and sample median 
            
----------------------------------------------------------------------------------------
  Data                     Median  Gene                    Sample Median                  
 ---------------------------------------------------------------------------------------- 
 Beer                       0.988±0.008                         0.989±0.008          
 Bhat                       0.971±0.003                         0.971±0.003          
 Garber                   0.980±0.010                         0.980±0.011          
---------------------------------------------------------------------------------------- 
 Mean                          0.913                                       0.913 
----------------------------------------------------------------------------------------- 
δ =10, K =100, k =10 and mean±SD representing 100 repeats   
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4.0  CONCLUSIONS AND DISUCUSSIONS 
An ideal prediction model would possess high prediction accuracy, model robustness, and model 
simplicity. To pursue these standards, we developed the MBP method, which borrowed 
information from genes sharing similar expression patterns. The goals of building the MBP 
model were to yield robust prediction models by solving gene noise and gene missing problems 
existing in the GBP and to obtain simple models by using all genes of a dataset to build 
prediction models without information of test datasets. The results of the current study showed 
that the prediction accuracies of the MBP method were not worse than those of the GBP method 
both within-study and inter-studies. However, the MBP method was superior to the GBP method 
in being both robust to gene noise and missing genes. Therefore, the MBP method would be 
useful for building a prediction model based on training data without information of test data. 
Nevertheless, there are three significant factors that need to be addressed for the MBP. 
As for model accuracy, it seems based on common sense that the GBP method would 
have higher prediction accuracies for specific datasets since genes selected into a prediction 
signature usually have higher differentiated values than those not selected. Thus, one might 
expect highly differentiated genes to be better than less differentiated genes at predicting patient 
outcome. However, gene signatures are not always unique. It has been shown that a gene 
signature may not always be unique for prediction models. It was originally shown in a seminal 
study that a 70-gene signature could predict breast cancer patient survival (van 't Veer, Dai et al. 
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2002). The investigators using the same dataset later identified an additional 6 classifiers of 
genes that performed equally well to the 70-gene signature (Ein-Dor, Kela et al. 2005). Also, 
disparity in using different gene signatures to predict similar outcomes has been reported (Sorlie, 
Perou et al. 2001; van 't Veer, Dai et al. 2002; Ramaswamy, Ross et al. 2003), which may lead to 
unstable predictions. The stability of the MBP method observed in the present study may be the 
result of grouping genes sharing a similar expression pattern and selecting a gene that can 
represent the group of genes. It has been postulated that using a cluster average would yield 
higher prediction accuracy under certain conditions (Park, Hastie et al. 2007). Although in this 
preliminary analysis, there was no significant difference in prediction accuracy between the GBP 
method and module based methods, both within study and cross-platform, the prediction 
accuracy might be affected by preset parameters. Different parameters should be tested in the 
near future. Even if the MBP method cannot surpass the GBP method in prediction accuracy, the 
prediction robustness remains its major advantage.                    
Regarding model simplicity, the clinical utility of a genomic prediction model relies 
heavily on the model's simplicity and reproducibility. Recent cross-platform analyses used 
intersection genes across datasets (Bloom, Yang et al. 2004; Bhanot, Alexe et al. 2005; Nilsson, 
Andersson et al. 2006; Bosotti, Locatelli et al. 2007; Cheadle, Becker et al. 2007), an approach 
that required information from all datasets involved in the analysis. This approach is good for 
cross- platform meta-analysis, but it is limited for cross-platform prediction. There are two 
elements needed for a prediction: 1) a selected gene signature and 2) a prediction model. A 
prediction is possible only when a test sample or partial test data is available. When intersection 
genes are used to build a prediction model, the selected prediction signature must be adjusted for 
new test samples, which would be inconvenient for model application. Furthermore, it may lose 
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information of training data by only including intersection genes to build the prediction model. 
Thus, the MBP method would be easier for application. 
In the sense of model reproducibility, lack of reproducibility hinders the application of 
genomic prediction models. Many factors may affect model reproducibility. The MBP method 
focuses on two factors to increase model reproducibility, missing genes, and gene noise. The 
robustness of the MBP method toward missing genes was proved by estimating the probability of 
model failure due to missing genes. The robustness of the method regarding gene noise was 
assessed by testing on the Luo dataset. This result is a quite common phenomenon in microarray 
data. Although the MBP method showed model robustness to added noise to the Luo data, the 
pattern of noise added may not totally mock all data variations. Further study will focus on 
adding different noises beside normal white noise and high variable data. 
Beside the value of the MBP contributing to clinical application, the MBP also added its 
value to microarray analysis methodology. First, this is the first time we identified that k-means 
cluster size followed a multinomial distribution and proposed a cluster merging step to avoid 
model prediction failure due to gene mismatch in microarray cross platform analysis. Second, we 
used a representative gene with the closest distance to all other genes within a module to 
summarize the module information, which is an actual gene with its annotation and interpretation 
rather than using extract information such as average gene expression or gene sample median. 
Third, the MBP reduced redundant features by summarizing similar gene expression profiles 
within each module, diminishing model collinearity and adding a novel technique for data 
reduction. The limitations of the MBP method are a lack of biological correlation information 
among the genes within each module and no enhancement of prediction accuracy, however, 
these issues lead to further investigation on the nature of the MBP method.  
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5.0  FUTURE DIRECTIONS 
Based on the results, the MBP method was proved to be plausible for the robust prediction of 
microarray cross-platform data and the goals of the study were achieved. However, the 
analyses were not near perfect to implement the validity and adequacy of the method. The 
further analyses will include the following topics:  
To compare the model accuracy and robustness with metagene method Although the 
other methods using cluster or group gene information instead of using individual gene 
information for prediction were not designed to achieve the same goal as the module based 
method was, these methods share the essence of using cluster of genes information. The 
prediction accuracies and robustness will be compared among these methods using same 
dataset.   
To compare the MBP with biological pathway modules MBP is an empirical data 
dimension reduction method. Though it can robustly predict patient outcome via inter-study 
data the mechanism of elements in a module is unknown. Biological pathway tools, such as 
GO, or KEEG, will be applied to check the biological relationships among the elements.    
To test the MBP in other biomarker platforms In this study, the MBP was evaluated in 
RNA expression microarray platforms. Based on the nature of high dimension data outputs of  
‘-omics’, the MBP can be extended to analyze DNA microarray, protein microarray, and 
metabolite mass spectra data. The MBP will be evaluated using other ‘-omics’ data.   
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